May 29, 2026

Dear Fellow Stockholders,

I would like to take this opportunity to provide an update to our valued stockholders regarding our fourth quarter 2025 financials and our preclinical rare disease program.

Select Q4 2025 Results (unaudited)

Our (unaudited) fourth quarter financial results are now available. The total revenue for the fourth quarter of 2025 was $226,000 compared to $156,000 for the same period in 2024. Gross profits for the fourth quarter of 2025 were $226,000 compared to $156,000 for the same period in 2024. Operating expenses for the fourth quarter of 2025 were ($275,000) compared to ($433,000) for the fourth quarter of 2024. The operating loss was ($49,000) in the fourth quarter of 2025 compared to ($277,000) in the fourth quarter of 2024. The company's non-cash stock expense fluctuates substantially from quarter to quarter. As a result, the company's management and board of directors exclude this expense from our operating expenses and from our operating losses during our internal analysis of the company's performance.

Select Financial Highlights (000's)

Item	***Q4 2025***	***Q4 2024***
Revenue	*$226*	*$156*
Gross Profits	*$226*	*$156*
Operating Expenses	*$275*	*$433*
Excluding Stock Expense	*$275*	*$339*
Operating profit (loss)	*($49)*	*($277)*
Excluding Stock Expense	*($49)*	*($183)*
Cash + A/R – A/P December 31	*1,465*	*$1,990*

Our licensing revenues are royalty-based and, therefore, carry no cost of goods. While royalty payments appear to be "pure profit," we must measure this royalty income against the costs required to support our ongoing patent obligations and the development/production costs required to support our licensing partners and generate new product opportunities. Our licensing activities continue to provide us with an ongoing royalty stream.

We currently have two primary licensed distributors of our peptide technologies into the personal care market. These partners command a strong presence in the marketplace and represent our portal to industry leaders that a small company such as ours could not easily and quickly access directly. The current macroeconomic situation and uncertainty about tariffs may impact distribution of both ingredients and skin care products.

As a reminder, due to our financial review schedule, we will be sharing our Q1 results for 2026 prior to our end-of year results for 2025. The fiscal year 2025 results will be shared in the stockholder letter that is mailed with our proxy. We also plan to post the letter on our website.

Rare Disease Program

Rare diseases are classified in the United States as those afflicting fewer than 200,000 individuals. The FDA has established the Orphan Drug Program to help incentivize companies to pursue drugs for the treatment of rare diseases. The Orphan Drug Act includes a number of incentives, currently including expanded access to the Investigational New Drug (IND) Program, grants for drug development, a waiver of user fees charged under the Prescription Drug User Fee Act (PDUFA), fast-track approvals, tax credits, and 7-year market exclusivity for an approved orphan drug.

Helix BioMedix is developing HB4208 for treatment of the rare disease, Xeroderma Pigmentosum (XP). XP is an inherited skin disorder characterized by hypersensitivity to the sun and ultraviolet (UV) rays. Individuals with XP are highly susceptible to DNA damage caused by UV light due to either lack of the normal repair mechanism or defective repair pathways to manage the damage. XP is a devastating disease for which there is currently no known cure and that significantly impacts both quality of life and life expectancy.

HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on repair pathways necessary to prevent cancerous mutations and maintain skin homeostasis. In early proof of concept work, the first-generation DDR enzyme demonstrated positive results to modulate UV-induced DNA damage and reduce skin lesions in an animal model. During 2024, our preclinical program focused on refinements in the structure of the protein enzyme to improve stability and manufacturing yields. Additionally, we implemented a study in disease-state XPA mice that looked at histological changes in UV exposed skin. Tissue analysis is currently being conducted.

In mid-June 2025, we submitted a request to the FDA for an INTERACT Meeting. INTERACT, or an **In**itial **T**argeted **E**ngagement for **R**egulatory **A**dvice on **C**BER/CDER Produc**T**s, is a meeting at a specific time early in product development. The appropriate timing for an INTERACT meeting is when a sponsor has identified the investigational product to be evaluated in a clinical study and conducted some preliminary preclinical proof-of-concept studies with the intended investigational product but has not yet designed and conducted definitive toxicology studies. Following our INTERACT meeting, we received a response from the FDA indicating that our current preclinical work was “reasonable” and that we could continue our plan to pursue a small microdosing study. We are currently working on developing the clinical protocol and supporting assays, and obtaining the necessary materials to be able to conduct the study. Although we intend to proceed with a small microdosing study, there is no assurance that this study will yield beneficial or helpful results, that the FDA will allow us to move forward with any subsequent studies, or that any such studies will ultimately lead to a commercialized product.

Patents

Helix BioMedix has a significant patent portfolio with over 200 patents worldwide. These patents expire in a range from mid-2027 to mid-2034.

Closing Comments

While there are significant challenges that must be overcome to get a new drug to market, we believe our preclinical program to develop HB4208 as a topical drug for the treatment of the rare dermatological condition, Xeroderma Pigmentosum, may provide an opportunity for additional long-term value creation, although there can be no assurance that this will transpire. The Helix BioMedix team is committed to excellence and dedicated to bringing new scientific innovation to the dermatology market.

Your management and Board are focused on the important tasks ahead of us and will inform you along the way as events unfold. Future progress and business highlights will continue to be posted on our website at www.helixbiomedix.com.

Sincerely,

Robin L. Carmichael
President & Chief Executive Officer
www.helixbiomedix.com

Forward Looking Statements

This document contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, interactions with the FDA, product development, feasibility of its rare disease program and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, continue its research and development efforts, including pre-clinical and clinical studies, develop effective drug candidates, obtain any necessary regulatory approvals from the FDA or otherwise, commercialize any products, enter into revenue generating license agreements, and general economic conditions. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.